Literature DB >> 17262742

Prediction of sites of recurrence in gastric carcinoma using immunohistochemical parameters.

Hiroaki Saito1, Tomohiro Osaki, Daiki Murakami, Teruhisa Sakamoto, Shingo Kanaji, Shotaro Ohro, Shigeru Tatebe, Shunichi Tsujitani, Masahide Ikeguchi.   

Abstract

BACKGROUND AND OBJECTIVES: To improve prognosis of patients with gastric cancer, it is important to detect recurrences at an early stage following surgery. If the site of recurrence can be predicted, recurrent disease can be easier detected at an early stage. However, this is difficult to achieve using normal clinicopathological factors. We aimed to predict sites of recurrence in patients with advanced gastric carcinoma who underwent curative resection.
METHODS: Expressions of vascular endothelial growth factor (VEGF), transforming growth factor (TGF)-ss1, and p53, together with density of microvessels (MVs), and dendritic cell (DC) infiltration were examined by immunohistochemistry to evaluate their relationships with recurrence patterns in patients with advanced gastric carcinoma (n = 92).
RESULTS: All immunohistochemical parameters closely correlated with prognosis (TGF-ss1, P = 0.008; VEGF, P < 0.001; p53, P = 0.028; MV, P < 0.001; DC, P < 0.001). Multivariate analysis showed that DC infiltration (P = 0.02; HR, 2.52; 95%CI, 1.16-5.48), MV density (P = 0.023; HR, 2.48; 95%CI, 1.13-5.44), VEGF expression (P = 0.002; HR, 3.27; 95%CI, 1.52-7.05), and lymph node metastasis (P < 0.0001; HR, 2.09; 95%CI, 1.49-2.93) were independent prognostic factors. A multivariate logistic regression analysis indicated that DC infiltration (P = 0.004; Odds ratio, 4.25; 95%CI, 1.51-11.96) and lymph node metastasis (P = 0.01; Odds ratio, 3.37; 95%CI, 1.31-8.66) provided significant estimates of relative risks for development of peritoneal recurrence. Upon development of hematogenous recurrence, VEGF expression significantly indicated relative risks (P < 0.001; Odds ratio, 7.26; 95%CI, 1.41-37.3). Moreover, p53 expression closely correlated with lymph node recurrence (P = 0.042; Odds ratio, 11; 95%CI, 1.26-95.7).
CONCLUSIONS: Assessment of immunohistochemical parameters can predict sites of recurrence in gastric carcinomas, and thus contributes to improve prognosis. (c) 2007 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17262742     DOI: 10.1002/jso.20612

Source DB:  PubMed          Journal:  J Surg Oncol        ISSN: 0022-4790            Impact factor:   3.454


  12 in total

1.  Prognostic significance of vascular endothelial growth factor immunohistochemical expression in gastric cancer: a meta-analysis.

Authors:  Ling Peng; Ping Zhan; Yun Zhou; Weijia Fang; Peng Zhao; Yulong Zheng; Nong Xu
Journal:  Mol Biol Rep       Date:  2012-06-23       Impact factor: 2.316

2.  Adjuvant chemotherapy, p53, carcinoembryonic antigen expression and prognosis after D2 gastrectomy for gastric adenocarcinoma.

Authors:  Ming-Ming He; Dong-Sheng Zhang; Feng Wang; Zhi-Qiang Wang; Hui-Yan Luo; Chao Ren; Ying Jin; Dong-Liang Chen; Rui-Hua Xu
Journal:  World J Gastroenterol       Date:  2014-01-07       Impact factor: 5.742

Review 3.  Roles of inflammatory cytokines in the progression of gastric cancer: friends or foes?

Authors:  Hironori Tsujimoto; Satoshi Ono; Takashi Ichikura; Yusuke Matsumoto; Junji Yamamoto; Kazuo Hase
Journal:  Gastric Cancer       Date:  2010-12-03       Impact factor: 7.370

Review 4.  Trial watch: Dendritic cell-based anticancer therapy.

Authors:  Norma Bloy; Jonathan Pol; Fernando Aranda; Alexander Eggermont; Isabelle Cremer; Wolf Hervé Fridman; Jitka Fučíková; Jérôme Galon; Eric Tartour; Radek Spisek; Madhav V Dhodapkar; Laurence Zitvogel; Guido Kroemer; Lorenzo Galluzzi
Journal:  Oncoimmunology       Date:  2014-12-21       Impact factor: 8.110

5.  CD83(+) dendritic cells and Foxp3(+) regulatory T cells in primary lesions and regional lymph nodes are inversely correlated with prognosis of gastric cancer.

Authors:  Seigo Kashimura; Zenichiro Saze; Masanori Terashima; Nobutoshi Soeta; Satoshi Ohtani; Fumihiko Osuka; Michihiko Kogure; Mitsukazu Gotoh
Journal:  Gastric Cancer       Date:  2011-11-15       Impact factor: 7.370

Review 6.  Potential therapeutic strategies for lymphatic metastasis.

Authors:  Bernadette M M Zwaans; Diane R Bielenberg
Journal:  Microvasc Res       Date:  2007-09-19       Impact factor: 3.514

7.  Prognostic value of vascular endothelial growth factor A expression in gastric cancer: a meta-analysis.

Authors:  Ya-nan Ji; Qin Wang; Yang Li; Zhi Wang
Journal:  Tumour Biol       Date:  2014-03

8.  Clinicopathological significance of platelet-derived growth factor (PDGF)-B and vascular endothelial growth factor-A expression, PDGF receptor-β phosphorylation, and microvessel density in gastric cancer.

Authors:  Shioto Suzuki; Yoh Dobashi; Yayoi Hatakeyama; Ryosuke Tajiri; Takashi Fujimura; Carl H Heldin; Akishi Ooi
Journal:  BMC Cancer       Date:  2010-11-30       Impact factor: 4.430

9.  Trial watch: Prognostic and predictive value of the immune infiltrate in cancer.

Authors:  Laura Senovilla; Erika Vacchelli; Jerome Galon; Sandy Adjemian; Alexander Eggermont; Wolf Hervé Fridman; Catherine Sautès-Fridman; Yuting Ma; Eric Tartour; Laurence Zitvogel; Guido Kroemer; Lorenzo Galluzzi
Journal:  Oncoimmunology       Date:  2012-11-01       Impact factor: 8.110

Review 10.  Trial watch: Dendritic cell-based interventions for cancer therapy.

Authors:  Erika Vacchelli; Ilio Vitale; Alexander Eggermont; Wolf Hervé Fridman; Jitka Fučíková; Isabelle Cremer; Jérôme Galon; Eric Tartour; Laurence Zitvogel; Guido Kroemer; Lorenzo Galluzzi
Journal:  Oncoimmunology       Date:  2013-07-29       Impact factor: 8.110

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.